secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2024-01-25T23:59:59+00:00
Accession:  0000950170-24-007480
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics regains Nasdaq minimum bid price compliance after reverse split
--------------------------------------------------------------------------------

- Received Nasdaq notice on Jan 23, 2024 confirming regained compliance with bid price rule.
- Company conducted a 1-for-10 reverse stock split on Jan 5, 2024 to help meet the $1.00 minimum close.
- Common shares met $1.00 closing bid for 10 consecutive trading days, ending the deficiency.
- Prior non-compliance notice was issued Jan 23, 2023; Nasdaq has now closed the matter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024007480/0000950170-24-007480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024007480/sabs-20240123.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-007480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer